Safety and long‐term outcomes after percutaneous coronary intervention in patients with human immunodeficiency virus. Issue 2 (17th June 2014)

• Record Type: Journal Article
• Authors: Badr, Salem; Minha, Sa'ar; Kitabata, Hironori; Fatemi, Omid; Torguson, Rebecca; Suddath, William O.; Satler, Lowell F.; Pichard, Augusto D.; Waksman, Ron
• Is Part Of: Catheterization and cardiovascular interventions. Volume 85:Issue 2(2015:Feb. 01)
• Page Start: 192
• Page End: 198
• Publication Date: 2014-06-17
• Subjects: Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.25466
• Languages: English
• ISSNs: 1522-1946

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ccd25466-sec-0001" sec-type="section"> <title>Objective</title> <p>This study aims to report the long‐term outcomes after percutaneous coronary intervention (PCI) in human immunodeficiency virus (HIV+) patients.</p> </sec> <sec id="ccd25466-sec-0002" sec-type="section"> <title>Background</title> <p>Sparse data exists regarding the risk of patients with HIV who undergo PCI.</p> </sec> <sec id="ccd25466-sec-0003" sec-type="section"> <title>Methods</title> <p>Using a case‐control design, we compared baseline characteristics, procedure‐related outcomes, in‐hospital, and 2‐year clinical outcomes of 112 consecutive HIV+ patients versus 112 HIV‐ controls matched for age, gender, and diabetes mellitus who underwent PCI from April 2003 to September 2011.</p> </sec> <sec id="ccd25466-sec-0004" sec-type="section"> <title>Results</title> <p>Baseline characteristics were generally comparable, save for more African Americans and history of chronic renal insufficiency in the HIV+ vs. HIV‐ group (62.5% vs. 21.4%, <italic>P</italic> < 0.001) and (27.7% vs. 9.9%, <italic>P</italic> < 0.001). There was no correlation between CD4 nadir count and extent and diffuseness of coronary artery disease. The occurrence of major adverse cardiac events at 2 years was similar in both groups. Multivariable analysis for independent correlates of major adverse cardiac events at 2 years detected patients with a history of chronic renal insufficiency (OR: 2.44, 95% confidence interval: 1.02–5.83; <italic>P</italic> = 0.04) and acute myocardial infarction (OR: 2.92, 95% confidence interval: 1.39–6.15; <italic>P</italic> = 0.005) as correlates for outcome. Post‐hoc analysis showed that drug‐eluting stent (DES) use in the HIV+ group was beneficial.</p> </sec> <sec id="ccd25466-sec-0005" sec-type="section"> <title>Conclusion</title> <p>PCI in HIV+ patients is safe, with high procedural success rates, and produces similar outcomes to those seen in HIV‐ patients at 2 years. HIV+ patients should be treated with DES if possible. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>